Literature DB >> 9506263

Human ochratoxicosis and nephropathy in Egypt: a preliminary study.

E W Wafa1, R S Yahya, M A Sobh, I Eraky, M el-Baz, H A el-Gayar, A M Betbeder, E E Creppy.   

Abstract

This preliminary study was designed in a trial to delineate the size of the problem of ochratoxicosis and its relation to genesis of lesions mounting to end stage renal disease (ESRD) or urothelial tumors in Egypt. This study comprised five groups of patients having renal diseases of different presentations; they are: patients with (ESRD) under conservative medical treatment (group 1), patients with (ESRD) under treatment with regular hemodialysis (group 2), renal allograft recipients (group 3), patients with nephrotic syndrome (group 4) and patients with urothelial tumors (group 5). In addition, two reference groups: potential related donors for renal transplantation (group 6) and healthy control with negative family history of renal disease (group 7). For all groups, laboratory, radiological and histopathological evaluation of kidney status were carried out coupled with determination of ochratoxin A level in serum, in urine and in biopsy specimens of patients with urothelial tumors. High ochratoxin serum levels were found in patients with ESRD (groups 1 and 2) (P < 0.01), higher serum levels were detected in the group without dialysis (group 1) in comparison with the reference groups possibly due to ochratoxin. A clearance by dialysis. Ochratoxin A was detected in serum and urine of renal transplant recipients (group 3) (P < 0.01) and especially higher levels were found in patients with nephrotic syndrome (group 4) (P < 0.001). For the group with urothelial tumor (group 5), positive serum, urine and tissue biopsy specimens for ochratoxin levels were found (P < 0.01). The results could lead to the conclusion that ochratoxin A could be correlated to the genesis of renal disease leading to (ESRD) or causing urothelial cancer. A thorough and in depth study of the problem of ochratoxicosis and renal disease causation in Egypt is now recommended.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506263     DOI: 10.1177/096032719801700207

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  25 in total

1.  A risk assessment of dietary Ochratoxin a in the United States.

Authors:  Nicole J Mitchell; Chen Chen; Jeffrey D Palumbo; Andreia Bianchini; Jack Cappozzo; Jayne Stratton; Dojin Ryu; Felicia Wu
Journal:  Food Chem Toxicol       Date:  2016-12-30       Impact factor: 6.023

2.  The effects of season and gender on the serum aflatoxins and ochratoxin A levels of healthy adult subjects from the Central Anatolia Region, Turkey.

Authors:  Suna Sabuncuoglu; Pinar Erkekoglu; Sevtap Aydin; Gönül Şahin; Belma Kocer-Gumusel
Journal:  Eur J Nutr       Date:  2014-07-25       Impact factor: 5.614

3.  Ochratoxin A blood concentration in healthy subjects and bladder cancer cases from Pakistan.

Authors:  M Aslam; A E Beg; M Blaszkewicz; G H Degen; K Golka
Journal:  Mycotoxin Res       Date:  2005-09       Impact factor: 3.833

4.  Microphysiological system modeling of ochratoxin A-associated nephrotoxicity.

Authors:  Tomoki Imaoka; Jade Yang; Lu Wang; Matthew G McDonald; Zahra Afsharinejad; Theo K Bammler; Kirk Van Ness; Catherine K Yeung; Allan E Rettie; Jonathan Himmelfarb; Edward J Kelly
Journal:  Toxicology       Date:  2020-09-06       Impact factor: 4.221

5.  Ochratoxin A is not detectable in renal and testicular tumours.

Authors:  Nader Fahmy; Mark Woo; Mona Alameldin; Kyle Macdonald; Lee W Goneau; Peter Cadieux; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

6.  Implications of fungal infections and mycotoxins in camel diseases in Saudi Arabia.

Authors:  Fardos M Bokhari
Journal:  Saudi J Biol Sci       Date:  2010-01       Impact factor: 4.219

7.  Ochratoxin A in human blood serum - retrospective long-term data.

Authors:  Erwin Märtlbauer; Ewald Usleber; Richard Dietrich; Elisabeth Schneider
Journal:  Mycotoxin Res       Date:  2009-09-15       Impact factor: 3.833

8.  The level of ochratoxin a in patients after nephrectomy.

Authors:  J Grajewski; P Jarzemski; M Twaruzek; K Kuzminska; M Trepala
Journal:  Mycotoxin Res       Date:  2007-03       Impact factor: 3.833

9.  Inhibition of the mitogen activated protein kinase ERK1/2 amplifies ochratoxin A toxicity in the proximal tubule of the kidney.

Authors:  C Sauvant; H Holzinger; M Gekle
Journal:  Mycotoxin Res       Date:  2003-06       Impact factor: 3.833

Review 10.  Ochratoxin A and human health risk: a review of the evidence.

Authors:  Travis R Bui-Klimke; Felicia Wu
Journal:  Crit Rev Food Sci Nutr       Date:  2015       Impact factor: 11.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.